Progress in medicinal chemistry. Vol. 45 /

• Άλλοι συγγραφείς: King, Frank D., Lawton, G.
• Μορφή: Ηλ. βιβλίο
• Γλώσσα: English
• Έκδοση: Amsterdam ; Oxford : Elsevier, 2007.
• Έκδοση: 1st ed.
• Σειρά: Progress in medicinal chemistry ; 45
• Θέματα: Pharmaceutical chemistry.; MEDICAL > Drug Guides.; MEDICAL > Pharmacology.; MEDICAL > Pharmacy.; MEDICAL > Nursing > Pharmacology.; Electronic books.

 The success of any drug discovery project relies upon the quality of the lead that initiates the lead optimization process. What defines a 'quality lead', where these 'quality leads' come from and how one discovers them has been the subject of intense debate within the pharmaceutical industry, relies upon defining those properties that historically have led to successful drug discovery. This volume addresses these questions and specifically discusses diabetes, obesity and tuberculosis. *Presents the latest research in the field of drug discovery *Publishes on an annual basis to bring you the most innovative updates in medicinal chemistry *Available as an online resource via ScienceDirect. 

 Cover -- Progress in Medicinal Chemistry 45 -- Copyright Page -- Contents -- Preface -- List of Contributors -- Chapter 1. Hit and Lead Identification: Efficient Practices for Drug Discovery -- Introduction -- Hit and Lead Identification Practices -- Lead Identification as Reported for Specific Targets -- Conclusion -- References -- Chapter 2. DPPIV Inhibition: Promising Therapy for the Treatment of Type 2 Diabetes -- Introduction -- Medicinal Chemistry and Preclinical Studies -- Clinical Data for Oral DPPIV Inhibitors -- Conclusions -- Authors Note -- References -- Chapter 3. Recent Progress Toward Nonpeptide Ligands for the Melanocortin-4 Receptor -- Introduction -- Cyclohexylpiperidines as Potent MC4R Agonists -- Cyclohexylpiperazines and Phenylpiperidines -- Phenylpiperazines as MC4R Agonists -- Other Classes of MC4R Agonists -- Compounds Mimicking a-MSH and its Peptide Analogues -- From Agonists to Antagonists -- Small Molecule MC4R Antagonists from Initial Screen Hits -- Other Nonpeptide MC4R Ligands -- Interaction of the MC4R with Ligands -- Medicinal Chemistry -- Conclusion -- References -- Chapter 4. Tuberculosis Chemotherapy: Recent Developments and Future Perspectives -- Introduction -- TB Drug Development Pipeline -- Potential New Drug Targets -- Concluding Comments -- Acknowledgments -- References -- Subject Index -- Author Index (Vols. 1- 45) -- Subject Index (Vols. 1- 45) -- Last Page.